Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assaysAxel Ducret, Sebastian Spindeldreher, Anaïs Manin et al.|mAbs|2021Cited by 57
Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug DevelopmentJochem Gokemeijer, Sofie Pattijn, Yi Wen et al.|The AAPS Journal|2023Cited by 22
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies DevelopmentJochem Gokemeijer, Vibha Jawa, Nanda Balasubramanian et al.|Clinical Pharmacology & Therapeutics|2023Cited by 9
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ ConsortiumJoanna Grudzinska‐Goebel, Vibha Jawa, Manuela Braun et al.|Nucleic Acid Therapeutics|2025Cited by 6